Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
October 23, 2019 at 04:56 am EDT
Share
Mayinglong Pharmaceutical Group Co., Ltd. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 1,922.956 million compared to CNY 1,592.273 million a year ago. Operating income was CNY 342.727 million compared to CNY 131.978 million a year ago. Net income was CNY 293.265 million compared to CNY 120.685 million a year ago. Basic earnings per share from continuing operations was CNY 0.68 compared to CNY 0.28 a year ago.
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. 
